Lexicon Pharmaceuticals | LXRX - Operating Expenses


Lexicon Pharmaceuticals reported $20.27M in Operating Expenses for its fiscal quarter ending in December of 2025.





Operating Expenses Change Date
Abbott USD 11.66B 1.2B Sep/2026
Acadia Pharmaceuticals USD 270.57M 450K Sep/2026
Agios Pharmaceuticals USD 155.3M 24.53M Jun/2026
Akebia Therapeutics USD 63.08M 8.26M Dec/2025
Alnylam Pharmaceuticals USD 1.11B 52.78M Sep/2026
AstraZeneca USD 11.55B 674M Sep/2026
BioMarin Pharmaceutical USD 819.04M 5.5B Sep/2026
Coherus Biosciences USD 51.83M 2.48M Dec/2025
Eli Lilly USD 10.52B 496M Jun/2026
Halozyme Therapeutics USD 198M 4.66M Sep/2026
Illumina USD 525M 374M Sep/2026
Insmed USD 606.26M 79.46M Sep/2026
Ironwood Pharmaceuticals USD 57.33M 8.63M Dec/2024
J&J USD 18.93B 1.09B Sep/2026
Lexicon Pharmaceuticals USD 20.27M 6.1M Dec/2025
MacroGenics USD 42.87M 21.68M Jun/2026
MannKind USD 104.44M 5.77M Sep/2026
Merck USD 10.75B 5.02B Sep/2026
Moderna USD 1.18B 223M Sep/2026
Novartis USD 9.88B 325M Sep/2026
PTC Therapeutics USD 211.54M 15.12M Jun/2026
Puma Biotechnology USD 49.26M 3.2M Jun/2024
Sarepta Therapeutics USD 390.39M 2.43M Sep/2026
Thermo Fisher Scientific USD 9.68B 134M Sep/2026
Ultragenyx Pharmaceutical USD 283M 6M Sep/2026
United Therapeutics USD 6.28B 124.3M Sep/2026
Vanda Pharmaceuticals USD -1.14B 1.6B Dec/2025